Hypertension: LCZ696, a novel dual inhibitor of neprilysin and the angiotensin II receptor, shows promise in phase II trial

Nature Reviews Nephrology

Volumn 6, Issue 7, 2010, Pages 383-

  Lucchese, Baldo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AHU 377; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; LCZ 696; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; PLACEBO; UNCLASSIFIED DRUG; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; HEART PROTECTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 77954238631     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.72     Document Type: Article

References (1)

1. Ruilope, L. M. et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 375, 1255-1266 (2010)